TC
ADPT icon

TAP Consulting’s Adaptive Biotechnologies ADPT Stock Holding History

TAP Consulting’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-131
Closed -$4K – 146
2021
Q4 		$4K Buy
+131
New +$4.01K ﹤0.01% 474

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

TAP Consulting's ADPT Position: Q1 2022 in Review

TAP Consulting sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 131 shares — an estimated $4K sold.

TAP Consulting first reported a position in ADPT in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

  • TAP Consulting reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
  • TAP Consulting sold 131 Adaptive Biotechnologies shares in Q1 2022, an estimated $4K.
  • TAP Consulting first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 1 quarter.
  • TAP Consulting's Adaptive Biotechnologies position peaked at $4K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.